Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis

被引:8
|
作者
Xia, Qianjing [1 ]
Lee, Myung Hee [2 ]
Walsh, Kathleen F. [2 ,3 ]
McAulay, Kathrine [2 ,4 ]
Bean, James M. [5 ]
Fitzgerald, Daniel W. [2 ,3 ,6 ]
Dupnik, Kathryn M. [2 ,3 ]
Johnson, Warren D. [2 ,3 ,6 ]
Pape, Jean W. [2 ,6 ]
Rhee, Kyu Y. [2 ,3 ,4 ]
Isa, Flonza [3 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
[2] Weill Cornell Med, Ctr Global Hlth, New York, NY 10065 USA
[3] Weill Cornell Med, Dept Med, 1300 York Ave,Room A-421, New York, NY 10065 USA
[4] Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Ctr GHESKIO, Port Au Prince, Haiti
关键词
N-1; N-12-DIACETYLSPERMINE; N-8-DIACETYLSPERMIDINE; DIAGNOSIS; SYSTEMS; HOST; TIME;
D O I
10.1172/jci.insight.136301
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND. Control of the tuberculosis (TB) pandemic remains hindered in part by a lack of simple and accurate measures of treatment efficacy, as current gold standard markers rely on sputum-based assays that are slow and challenging to implement. However, previous work identified urinary N-1, N-12-diacetylspermine (DiAcSpm), neopterin, hydroxykynurenine, N-acetylhexosamine, ureidopropionic acid, sialic acid, and mass-to-charge ratio (m/z) 241.0903 as potential biomarkers of active pulmonary TB (ATB). Here, we evaluated their ability to serve as biomarkers of TB treatment response and mycobacterial load. METHODS. We analyzed urine samples prospectively collected from 2 cohorts with ATB. A total of 34 study participants from African countries treated with first-line TB therapy rifampin, isoniazid, pyrazinamide, and ethambutol (HRZE) were followed for 1 year, and 35 participants from Haiti treated with either HRZE or an experimental drug were followed for 14 days. Blinded samples were analyzed by untargeted HPLC-coupled high-resolution TOF-mass spectrometry. RESULTS. Urinary levels of all 7 molecules significantly decreased by week 26 of successful treatment (P = 0.01 to P < 0.0001) and positively correlated with sputum mycobacterial load (P < 0.0001). Urinary DiAcSpm levels decreased significantly in participants treated with HRZE as early as 14 days (P < 0.0001) but remained unchanged in cases of ineffective therapy (P = 0.14). CONCLUSION. Urinary DiAcSpm, neopterin, hydroxykynurenine, N-acetylhexosamine, ureidopropionic acid, sialic acid, and m/z 241.0903 reductions correlated with successful anti-TB treatment and sputum mycobacterial load. Urinary DiAcSpm levels exhibited reductions capable of differentiating treatment success from failure as early as 2 weeks after the initiation of chemotherapy, advocating its further development as a potentially simple, noninvasive biomarker for assessing treatment response and bacterial load.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] SURGICAL-MANAGEMENT OF RESISTANT MYCOBACTERIAL TUBERCULOSIS AND OTHER MYCOBACTERIAL PULMONARY INFECTIONS
    POMERANTZ, M
    MADSEN, L
    GOBLE, M
    ISEMAN, M
    ANNALS OF THORACIC SURGERY, 1991, 52 (05): : 1108 - 1112
  • [22] Mycobacterial non-tuberculosis infection in patients operated on for pulmonary tuberculosis
    Aliev, Vilayat
    Lepeha, Larisa
    Krasnikova, Elena
    Smirnova, Tatyana
    Sadovnikova, Svetlana
    Bagirov, Mamad
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [23] The assessment of first-line anti-tuberculosis drug exposure, inflammatory biomarkers and pulmonary tuberculosis severity association with treatment response
    Igumnova, V.
    Kivrane, A.
    Viksna, A.
    Pahirko, L.
    Ozere, I.
    Bogdanova, I.
    Krams, A.
    Cirule, A.
    Grinberga, S.
    Sevostjanovs, E.
    Bandere, D.
    Ranka, R.
    FEBS OPEN BIO, 2022, 12 : 318 - 319
  • [24] Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis
    Said, Bibie N.
    Heysell, Scott K.
    Yimer, Getnet
    Aarnoutse, Rob E.
    Kibiki, Gibson S.
    Mpagama, Stellah
    Mbelele, Peter M.
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2021, 10 (04) : 457 - 462
  • [25] Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis
    Singanayagam, A.
    Manalan, K.
    Connell, D. W.
    Chalmers, J. D.
    Sridhar, S.
    Ritchie, A. I.
    Lalvani, A.
    Wickremasinghe, M.
    Kon, O. M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : 1653 - 1660
  • [26] Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis
    Ritchie, Andrew
    Singanayagam, Aran
    Manalan, Kavina
    Connell, David
    Chalmers, James
    Sridhar, Saranya
    Lalvani, Ajit
    Wickremasinghe, Melissa
    Kon, Onn Min
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [27] Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association With Disease Severity and Delayed Mycobacterial Clearance With Treatment
    Ralph, Anna P.
    Yeo, Tsin W.
    Salome, Cheryl M.
    Waramori, Govert
    Pontororing, Gysje J.
    Kenangalem, Enny
    Sandjaja
    Tjitra, Emiliana
    Lumb, Richard
    Maguire, Graeme P.
    Price, Ric N.
    Chatfield, Mark D.
    Kelly, Paul M.
    Anstey, Nicholas M.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (04): : 616 - 626
  • [28] MYCOBACTERIAL ANTIGEN-DETECTION BY IMMUNOHISTOCHEMISTRY IN PULMONARY TUBERCULOSIS
    HUMPHREY, DM
    WEINER, MH
    HUMAN PATHOLOGY, 1987, 18 (07) : 701 - 708
  • [29] SPECIFICITY OF ANTIBODIES TO IMMUNODOMINANT MYCOBACTERIAL ANTIGENS IN PULMONARY TUBERCULOSIS
    JACKETT, PS
    BOTHAMLEY, GH
    BATRA, HV
    MISTRY, A
    YOUNG, DB
    IVANYI, J
    JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (11) : 2313 - 2318
  • [30] IgA immune response against the mycobacterial antigen A60 in patients with active pulmonary tuberculosis
    Alifano, M
    Sofia, M
    Mormile, M
    Micco, A
    Mormile, AF
    DelPezzo, M
    Carratu, L
    RESPIRATION, 1996, 63 (05) : 292 - 297